The Rate of Re-treatment in Patients Treated with Teprotumumab A Multicenter Study of 119 Patients with 1 Year of Follow-up

Purpose: To determine the rate of re-treatment in patients who receive a full course of teprotumumab therapy for thyroid eye disease (TED) and drivers of re-treatment. Participants: All patients who received a full course of treatment and had available data at 1 year after initial treatment were included. Methods: Charts were reviewed for the following information: age, sex, months since diagnosis of TED, smoking status, and prior treatments. Further, the clinical activity score (CAS), proptosis, and the Gorman diplopia score were reviewed at baseline, at the end of the first course, and at baseline for the second course in those who received it. A logistic regression model was created to review the drivers of re-treatment. Main Outcome Measures: Rate of re-treatment and the drivers of re-treatment. Results: One hundred nineteen patients were included from 3 centers across the United States. The overall re-treatment rate was 24% (29/119). No difference was found among the 3 sites (P = 0.6). In univariable analyses, at baseline, no difference was found in proptosis (P = 0.07), diplopia score (P = 0.4), or duration of TED (P = 0.4) between patients who were re-treated and those not re-treated. From the re-treated group, 82% showed a significant proptosis response (>= 2-mm reduction from baseline) after the initial course, whereas 68% of patients who were not re-treated showed a clinically significant proptosis response (P = 0.16). The mean +/- standard deviation difference between the end of the first treatment and at baseline before the second treatment (in those who received it) was 2 +/- 2 for CAS, 2 +/- 4 mm for proptosis, and 1 +/- 1 for diplopia score. Age was the only significant driver of re-treatment (P < 0.05). Re-treated patients were 7 years older than patients who were not reConclusions: In patients receiving a full course of teprotumumab therapy, the rate of re-treatment was 24%. Financial Disclosure(s): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article. Ophthalmology 2025;132:92-97 (c) 2024 by the American Academy of Ophthalmology